Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0253977 |
id |
doaj-0919a58c67494a3f8b32fb73ff404f99 |
---|---|
record_format |
Article |
spelling |
doaj-0919a58c67494a3f8b32fb73ff404f992021-07-16T04:31:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025397710.1371/journal.pone.0253977Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.Serena MarchiSimonetta VivianiEdmond J RemarqueAntonella RuelloEmilio BombardieriValentina BollatiGregorio P MilaniAlessandro ManentiGiulia LapiniAnnunziata RebuffatEmanuele MontomoliClaudia M TrombettaSARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels.https://doi.org/10.1371/journal.pone.0253977 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Serena Marchi Simonetta Viviani Edmond J Remarque Antonella Ruello Emilio Bombardieri Valentina Bollati Gregorio P Milani Alessandro Manenti Giulia Lapini Annunziata Rebuffat Emanuele Montomoli Claudia M Trombetta |
spellingShingle |
Serena Marchi Simonetta Viviani Edmond J Remarque Antonella Ruello Emilio Bombardieri Valentina Bollati Gregorio P Milani Alessandro Manenti Giulia Lapini Annunziata Rebuffat Emanuele Montomoli Claudia M Trombetta Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. PLoS ONE |
author_facet |
Serena Marchi Simonetta Viviani Edmond J Remarque Antonella Ruello Emilio Bombardieri Valentina Bollati Gregorio P Milani Alessandro Manenti Giulia Lapini Annunziata Rebuffat Emanuele Montomoli Claudia M Trombetta |
author_sort |
Serena Marchi |
title |
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. |
title_short |
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. |
title_full |
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. |
title_fullStr |
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. |
title_full_unstemmed |
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. |
title_sort |
characterization of antibody response in asymptomatic and symptomatic sars-cov-2 infection. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2021-01-01 |
description |
SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels. |
url |
https://doi.org/10.1371/journal.pone.0253977 |
work_keys_str_mv |
AT serenamarchi characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT simonettaviviani characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT edmondjremarque characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT antonellaruello characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT emiliobombardieri characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT valentinabollati characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT gregoriopmilani characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT alessandromanenti characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT giulialapini characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT annunziatarebuffat characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT emanuelemontomoli characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection AT claudiamtrombetta characterizationofantibodyresponseinasymptomaticandsymptomaticsarscov2infection |
_version_ |
1721297923281518592 |